Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial)
Phlebology: The Journal of Venous Disease · 2025
DOI: 10.1177/02683555251375384 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Phlebology: The Journal of Venous Disease, 2025. Verfasst von Rebeca Higino Becker und 14 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Surgery Department, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Polidocanol, Sclerotherapy, Telangiectasis, Sclerosing Solutions. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Science Valley Research Institute.
Abstract (Originalsprache)
Background
Sclerotherapy with polidocanol is the gold standard treatment for telangiectasias and varicose veins, but technologies such as transdermal radiofrequency are also available. Transdermal radiofrequency (V Eraser ®) , a device that combines transdermal radiofrequency and sclerotherapy, was developed to treat these conditions.
Methods
This was a prospective, randomized, and comparative study between transdermal radiofrequency and sclerotherapy for treating telangiectasias and reticular veins. Forty-one patients were randomized to either transdermal radiofrequency plus polidocanol sclerotherapy or polidocanol sclerotherapy alone and underwent a single treatment session. Efficacy was assessed using vessel clearance analysis in pre- and post-treatment images and the Aberdeen Varicose Vein Questionnaire.
Results
Forty-six patients were enrolled. Both treatments significantly reduced vessel length in a single session ( p < .001). Sclerotherapy showed an average reduction of 30.7%, while transdermal radiofrequency reduced it by 33%, with no statistically significant difference ( p = .596). Quality of life improved, with pain reduction in 40% and 55% of patients in the right and left lower limbs, respectively ( p = .030 and p = .002).
Conclusion
Transdermal radiofrequency was not superior to standard of care polidocanol sclerotherapy. Both methods improved quality of life, particularly in reducing pain associated with varicose veins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vascular Surgery Department, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brazil.
- Vascular Surgery Department, Centro Universitário São Lucas Ji-Paraná, Rondônia, Brazil.
- Vascular Surgery Department, Universidade do Rio Grande - FURG, Rio Grande, Rio Grande do Sul, Brazil.
- Clinical Trials Department, Science Valley Research Institute, São Paulo, Brazil.
- Vascular Surgery Department, Universidade Federal de Goiás, Goiânia, Brazil.
- Haemostasis & Thrombosis Research Laboratories, Loyola University Medical Centre, Maywood, IL, USA.
ORCID-Profile: Rebeca Higino Becker, Caroline Cândida Carvalho de Oliveira, Rafaela Palermo Marcondes, Ariadne Ribeiro Negrão, Flávia Magella, Giuliano Giova Volpiani, Samantha Neves, Renata Camila Barros Rodrigues, Mariana Ferreira Borges Firmo Rodrigues, Viviane Santana da Silva, Camilla Moreira Ribeiro, Rodrigo Kikuchi, Eduardo Ramacciotti
Förderung
- Science Valley Research Institute
Zitieren
APA
Higino Becker, R., Caffaro, R. A., de Oliveira, C. C. C., Marcondes, R. P., Negrão, A. R., Magella, F., Volpiani, G. G., Neves, S., Rodrigues, R. C. B., Rodrigues, M. F. B. F., da Silva, V. S., Ribeiro, C. M., Kikuchi, R., Santiago, F. R., & Ramacciotti, E. (2025). Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial). Phlebology: The Journal of Venous Disease. https://doi.org/10.1177/02683555251375384
Vancouver
Higino Becker R, Caffaro RA, de Oliveira CCC, Marcondes RP, Negrão AR, Magella F, et al. Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial). Phlebology: The Journal of Venous Disease. 2025. doi:10.1177/02683555251375384
BibTeX
@article{HiginoBecker2025,
author = {Higino Becker, Rebeca and Caffaro, Roberto Augusto and de Oliveira, Caroline Cândida Carvalho and Marcondes, Rafaela Palermo and Negrão, Ariadne Ribeiro and Magella, Flávia and Volpiani, Giuliano Giova and Neves, Samantha and Rodrigues, Renata Camila Barros and Rodrigues, Mariana Ferreira Borges Firmo and da Silva, Viviane Santana and Ribeiro, Camilla Moreira and Kikuchi, Rodrigo and Santiago, Fabricio Rodrigues and Ramacciotti, Eduardo},
title = {Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial)},
journal = {Phlebology: The Journal of Venous Disease},
year = {2025},
doi = {10.1177/02683555251375384}
}
EUVIMED